Certified by Founder Lodge
Marshall Wace
United Kingdom - London
INVESTOR
1 Disclosed Funding Rounds $120,000,000
13 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Founded in 1997, Marshall Wace is a global asset manager offering a diverse set of alternative, long-only and bespoke investment solutions to a broad range of investors.
| Company | Date | Round | Raised |
|---|---|---|---|
 BlueWhale Bio |
September, 08 ,2023 | Unknown | $18,000,000 |
 Turtlemint |
April, 29 ,2022 | Series E | $120,000,000 |
 Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
 FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
 Prognos Health |
May, 18 ,2023 | Unknown | $23,000,000 |
 Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
 ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
 Inquis Medical, Inc. |
November, 05 ,2024 | Series B | $40,000,000 |
 Beta Bionics |
September, 04 ,2023 | Series D | $100,000,000 |
| BlueWhale Bio |
September, 08 ,2023 | Unknown | $18,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
| Inquis Medical, Inc. |
November, 05 ,2024 | Series B | $40,000,000 |
dezerv.
FalconX
Kristal.AI
Finary
Savart
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
